by Team PCM | Sep 14, 2022 | Blog post, Biosimilars, Drug Pricing
Biosimilar drugs are “highly similar to” and have “no clinically meaningful differences” from existing FDA-approved biologics. Currently, there are 38 biosimilars on the market, giving patients safe, cost-effective alternatives to high-cost biologics. Adoption of...
